Biohaven Pharmaceuticals Quarterly Balance Sheets Chart
Quarterly
|
Annual
Biohaven Pharmaceuticals Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||
| current assets: | |||||||||||||||||||
| cash and cash equivalents | 235,807,000 | 169,065,000 | 171,945,000 | 501,409,000 | 306,267,000 | 464,714,000 | 132,149,000 | 316,231,000 | |||||||||||
| marketable securities | 317,679,000 | 433,410,000 | 192,648,000 | 19,031,000 | 59,840,000 | 101,547,000 | 223,185,000 | 229,983,000 | |||||||||||
| trade receivable | 352,449,000 | 328,342,000 | 252,952,000 | 168,637,000 | 156,769,000 | ||||||||||||||
| inventory | 106,561,000 | 91,281,000 | 74,864,000 | 64,058,000 | 58,329,000 | ||||||||||||||
| prepaid expenses | 100,360,000 | 104,891,000 | 88,838,000 | 61,698,000 | 48,871,000 | ||||||||||||||
| other current assets | 61,485,000 | 44,096,000 | 33,946,000 | 34,427,000 | 18,907,000 | ||||||||||||||
| total current assets | 1,174,341,000 | 1,171,085,000 | 876,254,000 | 944,381,000 | 666,580,000 | 900,696,000 | 603,406,000 | 708,285,000 | 362,562,000 | 474,446,000 | 328,281,000 | 423,170,000 | 474,352,000 | 227,373,000 | 272,339,000 | 182,980,000 | 227,602,000 | 114,673,000 | 53,169,000 |
| property and equipment | 15,727,000 | 14,534,000 | 14,690,000 | 10,409,000 | 10,885,000 | 11,258,000 | 9,340,000 | 8,802,000 | 8,979,000 | 8,933,000 | 8,152,000 | 7,460,000 | 7,433,000 | 7,157,000 | 6,248,000 | 4,891,000 | 3,792,000 | 2,936,000 | 43,000 |
| intangible assets | 75,112,000 | 55,910,000 | 56,438,000 | 56,968,000 | 57,501,000 | 58,226,000 | 39,087,000 | 39,811,000 | 40,535,000 | 41,259,000 | |||||||||
| other assets | 121,069,000 | 130,188,000 | 129,830,000 | 119,437,000 | 110,927,000 | 32,979,000 | 33,966,000 | 23,251,000 | 9,706,000 | 4,073,000 | 2,493,000 | 1,351,000 | 24,000 | 36,000 | 11,000 | 64,000 | 43,000 | 32,000 | |
| total assets | 1,386,249,000 | 1,371,717,000 | 1,077,212,000 | 1,131,195,000 | 845,893,000 | 1,003,159,000 | 686,975,000 | 782,015,000 | 424,255,000 | 532,669,000 | 344,264,000 | 439,087,000 | 490,908,000 | 245,080,000 | 290,012,000 | 195,091,000 | 239,290,000 | 126,135,000 | 60,191,000 |
| liabilities and shareholders’ deficit | |||||||||||||||||||
| current liabilities: | |||||||||||||||||||
| accounts payable | 64,149,000 | 56,202,000 | 51,683,000 | 49,437,000 | 60,002,000 | 64,571,000 | 48,476,000 | 43,976,000 | 17,044,000 | 29,703,000 | 14,071,000 | 11,562,000 | 13,502,000 | 8,210,000 | 10,752,000 | 4,658,000 | 4,027,000 | 9,051,000 | 4,022,000 |
| accrued expenses and other current liabilities | 545,307,000 | 457,412,000 | 420,019,000 | 350,339,000 | 276,630,000 | 268,720,000 | 165,784,000 | 126,267,000 | 118,123,000 | 76,770,000 | |||||||||
| current portion of mandatorily redeemable preferred shares | 62,500,000 | 62,500,000 | 62,500,000 | 62,500,000 | 62,500,000 | 62,500,000 | 62,500,000 | 46,875,000 | 31,250,000 | 15,625,000 | |||||||||
| total current liabilities | 671,956,000 | 576,114,000 | 534,202,000 | 462,276,000 | 399,132,000 | 395,791,000 | 276,760,000 | 217,118,000 | 166,417,000 | 122,098,000 | 66,173,000 | 47,206,000 | 44,669,000 | 23,693,000 | 19,534,000 | 15,264,000 | 12,755,000 | 16,865,000 | 15,442,000 |
| long-term debt | 764,983,000 | 634,106,000 | 626,720,000 | 619,267,000 | 274,138,000 | 270,756,000 | 267,458,000 | 264,135,000 | |||||||||||
| liability related to sale of future royalties | 388,027,000 | 377,998,000 | 367,645,000 | 357,655,000 | 347,384,000 | 339,020,000 | 328,350,000 | 318,594,000 | 160,805,000 | 151,454,000 | 144,111,000 | 136,799,000 | 129,487,000 | 124,332,000 | 111,919,000 | 106,282,000 | |||
| mandatorily redeemable preferred shares | 180,213,000 | 162,994,000 | 155,737,000 | 144,333,000 | 133,091,000 | 122,119,000 | 111,591,000 | 119,456,000 | 127,771,000 | 136,404,000 | 103,646,000 | 99,268,000 | 94,890,000 | ||||||
| derivative liabilities | 110,129,000 | 14,190,000 | 1,940,000 | ||||||||||||||||
| obligation to perform r&d services | 29,972,000 | 36,016,000 | 50,571,000 | 47,155,000 | 55,353,000 | 60,530,000 | |||||||||||||
| other long-term liabilities | 46,527,000 | 41,782,000 | 12,236,000 | 16,666,000 | 17,501,000 | 18,698,000 | 20,815,000 | 14,590,000 | 4,728,000 | 105,000 | 68,000 | 43,000 | 43,000 | 44,000 | 2,043,000 | 2,095,000 | 1,423,000 | 1,454,000 | 19,000 |
| total liabilities | 2,191,807,000 | 1,838,130,000 | 1,760,221,000 | 1,662,402,000 | 1,242,489,000 | 1,221,314,000 | 1,019,164,000 | 935,833,000 | 459,721,000 | 410,711,000 | 351,688,000 | 320,111,000 | 304,167,000 | 148,069,000 | 139,092,000 | 129,278,000 | 120,460,000 | 18,319,000 | 39,833,000 |
| commitments and contingencies | |||||||||||||||||||
| contingently redeemable non-controlling interests | 60,000,000 | 60,000,000 | 60,000,000 | 60,000,000 | 60,000,000 | 60,000,000 | |||||||||||||
| shareholders’ deficit: | |||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of june 30, 2022 and december 31, 2021; 71,111,071 and 66,933,531 shares issued and outstanding as of june 30, 2022 and december 31, 2021, respectively | 2,181,398,000 | ||||||||||||||||||
| additional paid-in capital | 167,021,000 | 129,580,000 | 169,656,000 | 165,052,000 | 142,405,000 | 123,731,000 | 98,938,000 | 103,419,000 | 91,773,000 | 92,129,000 | 83,523,000 | 67,496,000 | 58,717,000 | 46,538,000 | 40,104,000 | 36,358,000 | 32,982,000 | 28,194,000 | 20,371,000 |
| accumulated other comprehensive loss | -5,811,000 | -2,398,000 | |||||||||||||||||
| accumulated deficit | -3,143,541,000 | -2,702,154,000 | -2,585,755,000 | -2,386,572,000 | -2,214,756,000 | -2,004,137,000 | -1,739,169,000 | -1,521,433,000 | -1,326,244,000 | -1,145,310,000 | -972,373,000 | -823,109,000 | -716,942,000 | -505,872,000 | -443,568,000 | -388,818,000 | -327,377,000 | ||
| total shareholders’ deficit attributable to biohaven pharmaceutical holding company ltd. | -800,933,000 | -462,286,000 | -739,380,000 | -587,976,000 | -453,877,000 | -275,976,000 | -390,370,000 | ||||||||||||
| non-controlling interests in consolidated subsidiaries | -4,625,000 | -4,127,000 | -3,629,000 | -3,231,000 | -2,719,000 | -2,179,000 | -1,819,000 | ||||||||||||
| total shareholders' deficit | -805,558,000 | -466,413,000 | -743,009,000 | -591,207,000 | -456,596,000 | -278,155,000 | -392,189,000 | ||||||||||||
| total liabilities and shareholders’ deficit | 1,386,249,000 | 1,371,717,000 | 1,131,195,000 | 845,893,000 | 1,003,159,000 | ||||||||||||||
| derivative liability | 9,120,000 | 13,110,000 | 15,050,000 | 15,890,000 | 14,400,000 | 650,000 | 37,690,000 | 36,795,000 | 35,078,000 | 223,000 | |||||||||
| common shares, no par value; 200,000,000 shares authorized as of march 31, 2022 and december 31, 2021; 70,540,802 and 66,933,531 shares issued and outstanding as of march 31, 2022 and december 31, 2021, respectively | 2,112,686,000 | ||||||||||||||||||
| trade receivables | 308,269,000 | 79,522,000 | 44,796,000 | 4,337,000 | |||||||||||||||
| inventories | 80,608,000 | 39,563,000 | 20,131,000 | 8,970,000 | 4,582,000 | ||||||||||||||
| equity method investment | 1,176,000 | 1,866,000 | 2,473,000 | 3,958,000 | 5,338,000 | 7,106,000 | 9,099,000 | 10,514,000 | 11,414,000 | 7,156,000 | 7,853,000 | 8,494,000 | 4,511,000 | ||||||
| liabilities and shareholders' deficit | |||||||||||||||||||
| shareholders' deficit: | |||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of december 31, 2021 and 2020; 66,933,531 and 60,436,876 shares issued and outstanding as of december 31, 2021 and december 31, 2020, respectively | 1,676,792,000 | ||||||||||||||||||
| accumulated other comprehensive income | -73,000 | 82,000 | 280,000 | 409,000 | 314,000 | 251,000 | |||||||||||||
| total liabilities and shareholders' deficit | 1,077,212,000 | 686,975,000 | 424,255,000 | ||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of september 30, 2021 and december 31, 2020; 65,473,332 and 60,436,876 shares issued and outstanding as of september 30, 2021 and december 31, 2020, respectively | 1,633,462,000 | ||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of june 30, 2021 and december 31, 2020; 65,240,458 and 60,436,876 shares issued and outstanding as of june 30, 2021 and december 31, 2020, respectively | 1,618,194,000 | ||||||||||||||||||
| prepaid expenses and other current assets | 119,337,000 | 88,398,000 | 62,418,000 | 47,735,000 | 37,288,000 | 11,554,000 | 6,596,000 | 8,613,000 | 9,966,000 | 8,090,000 | 14,795,000 | 10,150,000 | 10,467,000 | 883,000 | |||||
| common shares, no par value; 200,000,000 shares authorized as of march 31, 2021 and december 31, 2020; 65,066,468 and 60,436,876 shares issued and outstanding as of march 31, 2021 and december 31, 2020, respectively | 1,604,021,000 | ||||||||||||||||||
| trade receivables, net of allowance | 120,111,000 | ||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of december 31, 2020 and 2019; 60,436,876 and 44,197,549 shares issued and outstanding as of december 31, 2020 and december 31, 2019, respectively | 1,249,547,000 | ||||||||||||||||||
| liabilities and shareholders’ equity | |||||||||||||||||||
| shareholders’ equity | |||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of september 30, 2020 and december 31, 2019; 59,707,780 and 52,385,283 shares issued and outstanding as of september 30, 2020 and december 31, 2019, respectively | 1,205,384,000 | ||||||||||||||||||
| total shareholders’ equity (deficit) attributable to biohaven pharmaceutical holding company ltd. | -212,379,000 | ||||||||||||||||||
| non-controlling interests | -1,439,000 | ||||||||||||||||||
| total shareholders' equity | -213,818,000 | -7,424,000 | 150,920,000 | ||||||||||||||||
| total liabilities and shareholders' equity | 782,015,000 | 344,264,000 | |||||||||||||||||
| cash | 261,061,000 | 428,239,000 | 316,727,000 | 416,574,000 | 465,739,000 | 217,407,000 | 264,249,000 | 168,185,000 | 217,452,000 | 104,206,000 | 52,286,000 | ||||||||
| common shares, no par value; 200,000,000 shares authorized as of june 30, 2020 and december 31, 2019; 59,525,565 and 52,385,283 shares issued and outstanding as of june 30, 2020 and december 31, 2019, respectively | 1,199,005,000 | ||||||||||||||||||
| total shareholders’ deficit | -35,466,000 | ||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of march 31, 2020 and december 31, 2019; 58,387,948 and 52,385,283 shares issued and outstanding as of march 31, 2020 and december 31, 2019, respectively | 1,175,139,000 | ||||||||||||||||||
| total shareholders’ equity | 121,958,000 | 118,976,000 | 186,741,000 | 97,011,000 | 65,813,000 | 118,830,000 | 107,816,000 | ||||||||||||
| total liabilities and shareholders’ equity | 532,669,000 | 439,087,000 | 490,908,000 | 245,080,000 | 195,091,000 | 239,290,000 | 126,135,000 | ||||||||||||
| liabilities and shareholders' equity | |||||||||||||||||||
| accrued expenses | 52,102,000 | 35,644,000 | 31,167,000 | 15,483,000 | 8,782,000 | 10,606,000 | 8,728,000 | 7,814,000 | 6,931,000 | ||||||||||
| shareholders' equity: | |||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of december 31, 2019 and 2018; 52,385,283 and 44,197,549 shares issued and outstanding as of december 31, 2019 and december 31, 2018, respectively | 881,426,000 | ||||||||||||||||||
| shareholders’ equity: | |||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of september 30, 2019 and december 31, 2018; 52,217,684 and 44,197,549 shares issued and outstanding as of september 30, 2019 and december 31, 2018, respectively | 874,589,000 | ||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of june 30, 2019 and december 31, 2018; 51,501,614 and 44,197,549 shares issued and outstanding as of june 30, 2019 and december 31, 2018, respectively | 844,966,000 | ||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of march 31, 2019 and december 31, 2018; 44,282,994 and 44,197,549 shares issued and outstanding as of march 31, 2019 and december 31, 2018, respectively | 556,345,000 | ||||||||||||||||||
| non-recourse debt related to sale of future royalties | 117,515,000 | ||||||||||||||||||
| warrant liability | 1,234,000 | ||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of december 31, 2018 and 2017; 44,197,549 and 36,057,748 shares issued and outstanding as of december 31, 2018 and december 31, 2017, respectively | 554,384,000 | ||||||||||||||||||
| total liabilities, convertible preferred shares and shareholders' equity | 290,012,000 | ||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of september 30, 2018 and december 31, 2017; 40,261,750 and 36,057,748 shares issued and outstanding as of september 30, 2018 and december 31, 2017, respectively | 418,273,000 | ||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of june 30, 2018 and december 31, 2017; 40,094,291 and 36,057,748 shares issued and outstanding as of june 30, 2018 and december 31, 2017, respectively | 413,225,000 | ||||||||||||||||||
| common shares, no par value; 200,000,000 shares authorized as of march 31, 2018 and december 31, 2017; 38,607,017 and 36,057,748 shares issued and outstanding as of march 31, 2018 and december 31, 2017, respectively | 367,730,000 | ||||||||||||||||||
| restricted cash | |||||||||||||||||||
| deferred offering costs | 2,399,000 | ||||||||||||||||||
| deferred tax assets | 9,000 | ||||||||||||||||||
| liabilities, convertible preferred shares and shareholders’ equity | |||||||||||||||||||
| notes payable, net of discount | 4,489,000 | ||||||||||||||||||
| contingent equity liability | 22,313,000 | ||||||||||||||||||
| notes payable to related parties | 602,000 | ||||||||||||||||||
| series a convertible preferred shares, no par value; 11,242,172 shares authorized as of march 31, 2017 and december 31, 2016; 9,358,560 and 4,948,369 shares issued and outstanding as of march 31, 2017 and december 31, 2016, respectively; aggregate liquidation preference of 86,951 and 45,976 as of march 31, 2017 and december 31, 2016, respectively | 73,900,000 | ||||||||||||||||||
| common shares, no par value; 38,000,000 shares authorized as of march 31, 2017 and december 31, 2016; 13,121,000 and 13,088,500 shares issued and outstanding as of march 31, 2017 and december 31, 2016, respectively | 20,296,000 | ||||||||||||||||||
| total liabilities, convertible preferred shares and shareholders’ equity | 60,191,000 |
We provide you with 20 years of balance sheets for Biohaven Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Biohaven Pharmaceuticals. Explore the full financial landscape of Biohaven Pharmaceuticals stock with our expertly curated balance sheets.
The information provided in this report about Biohaven Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.